MedTrace Logo

DepoCyt for Active Lymphomatous or Leukemic Meningitis

NCT00523939 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2013-06-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the response rate of lymphomatous meningitis or leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well to the study drug, and the response of symptoms to the study drug will also be determined.

Conditions

  • Neoplastic Meningitis
  • Lymphoma, B Cell

Interventions

DRUG

cytarabine liposome injection

50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses

Sponsors & Collaborators

  • Enzon Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • David Rizzieri, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523939 on ClinicalTrials.gov